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Versican is upregulated in circulating monocytes
in patients with systemic sclerosis and amplifies
a CCL2-mediated pathogenic loop
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Abstract
Introduction: Altered phenotypes of circulating monocytes of patients with systemic sclerosis (SSc) have been
reported, but the role of these alterations in the pathogenesis of SSc remains unclear. This study was undertaken
to identify molecules that are preferentially expressed by SSc monocytes, and to investigate the roles of these
molecules in the pathogenic process of SSc.
Methods: We analyzed circulating CD14+ monocytes isolated from 36 patients with SSc and 32 healthy control
subjects. The monocytes’ gene expression profiles were assessed by Oligo GEArray® (SABiosciences, Frederic, MA,
USA) and semiquantitative or quantitative PCR; their protein expression was evaluated in culture supernatants of
unstimulated monocytes by immunoblotting or ELISA, and by immunocytostaining. Monocyte chemoattractant
activity of CCL2 was assessed in a TransWell® system (Corning Incorporated, Corning, NY, USA) in the presence or
absence of chondroitin sulfate (CS).
Results: A step-wise approach to profiling gene expression identified that versican and CCL2 were upregulated in
SSc monocytes. Subsequent analysis of proteins expressed in monocyte culture supernatants confirmed enhanced
production of versican and CCL2 in SSc monocytes compared with control monocytes. CCL2 bound to CS chains
of versican and colocalized with versican in the monocytes’ Golgi apparatus. Finally, CCL2 had a greater ability to
mediate monocyte migration when bound to CS chains, because this binding provided efficient formation of CCL2
gradients and protection from protease attack.
Conclusion: Circulating monocytes with elevated versican and CCL2 levels may contribute to the fibrotic process
in a subset of SSc patients by amplifying a positive feedback loop consisting of versican, CCL2, and the influx of
monocytes.
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Introduction
Systemic sclerosis (SSc) is a multisystem disease charac-
terized by microvascular abnormalities and excessive
fibrosis [1]. Current research suggests that the pathogenic
process of SSc damages endothelial cells and activates
immune cells and fibroblasts, causing excessive accumu-
lation of extracellular matrix (ECM) [2]. Mononuclear
cell infiltration, consisting predominantly of macrophages
and T cells, has been detected histopathologically in SSc
lesions in the skin, lung, and other tissues, especially in
the early phases of SSc [3,4]. Tissue macrophages in the
perivascular skin express activation markers such as
HLA-DR, platelet-derived growth factor B receptor [5],
and CD163 [6]. Activated macrophages in the skin express
CD204 [6], a marker for the M2 macrophages that are
associated with wound repair and fibrotic conditions [7].
A recent study of lung tissue in SSc patients with intersti-
tial lung disease found prominent infiltrates of fibrocytes
expressing CD34, CD45, and collagen type I [8]; precur-
sors of cells expressing these markers are found among
circulating CD14+ monocytes [9]. These findings indicate
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that monocytes and monocyte-lineage cells are actively
involved in the pathophysiology of SSc.
Circulating CD14+ monocytes derive from hematopoie-
tic stem cells in the bone marrow and migrate to their
ultimate sites of activity, and form a heterogeneous popu-
lation in terms of surface markers, phagocytic capacity,
and differentiation potential. Although circulating mono-
cytes are committed precursors with the capacity to
differentiate into a variety of phagocytes, including
macrophages and dendritic cells, there is growing evi-
dence that these monocytes can differentiate into other
cell types as well, including cells with the typical charac-
teristics of endothelial cells and fibroblasts [10-13].
Circulating monocytes are now recognized as multifunc-
tional precursors, playing critical roles not only in
immune and inflammatory responses but also in tissue
regeneration and in pathologic tissue remodeling, such as
excessive fibrosis and tumor development [13,14].
CD14+ monocytes are increased in peripheral blood of
SSc patients [6], and the molecular phenotypes and the
proportions of cell types in the population are altered,
with a larger proportion of type I collagen-producing
monocytes [15], CXCR4+ circulating cells with monocytic
and endothelial features [16], monocytic proangiogenic
hematopoietic cells [17], and CD163+CD204+ cells with a
profibrotic M2 phenotype [6]. Moreover, recent microar-
ray analyses of circulating monocytes identified several
genes that are overexpressed in SSc monocytes, including
type I interferon-regulated genes such as Siglec-1 [18,19].
The SSc pathogenic process thus probably recruits circu-
lating monocytes to the affected sites, where they acquire
profibrotic properties. Although the details are still
unclear, there may be at least two distinct mechanisms
underlying profibrotic properties of these monocytes -
the production of a variety of profibrotic growth factors,
cytokines, and chemokines, including transforming
growth factor beta and platelet-derived growth factor [2],
and their transdifferentiation into ECM-producing cells
[10,11,20].
In this study, we evaluated the gene and protein expres-
sion profiles of circulating CD14+ monocytes in patients
with SSc, using a high-throughput platform. We were par-
ticularly interested in genes related to ECM metabolism,




This study included 36 patients (four men and 32 women)
who met the preliminary SSc classification criteria pro-
posed by the American College of Rheumatology [21].
Using the published criteria, 19 patients were classified as
having diffuse cutaneous SSc (dcSSc) and 17 as having
limited cutaneous SSc (lcSSc) [22]. The study included
32 healthy control subjects (16 men and 16 women). The
average age at the time of examination was 55.3 ± 15.9 in
SSc patients and 45.8 ± 19.3 in control subjects.
Organ involvement related to SSc was defined for each
patient as described previously [23]. SSc-related autoanti-
bodies were identified by indirect immunofluorescence
using commercially prepared slides of monolayer HEp-2
cells (MBL, Nagano, Japan) and immunoprecipitation
assays [23]. The mean disease duration from onset of
Raynaud’s phenomenon was 13.6 ± 10.4 years. In patients
with dcSSc, 13 of 19 were in late phase, with disease
duration >5 years from the onset of non-Raynaud’s phe-
nomenon symptoms. Table 1 presents patients’ autoanti-
body profiles, SSc-related organ involvement, and
medications reported at the time of blood collection.
Before collecting blood samples, we obtained written,
informed consent from both patients and control sub-
jects in accord with the tenets of the Declaration of
Helsinki, and as approved by the International Review
Board of Keio University.




Joint contractures 16 (44%)
Esophageal hypomotility 24 (67%)
Cardiac involvement 1 (3%)
Renal involvement 1 (3%)
Interstitial lung disease 22 (62%)
Pulmonary arterial hypertension 1 (3%)
Digital pitting scars 18 (50%)
Systemic sclerosis-related autoantibodiesa
Anti-topoisomerase I 16 (44%)
Anticentromere 7 (19%)
Anti-RNA polymerase III 2 (6%)
Anti-U1 ribonucleoprotein 7 (19%)
Anti-Th/To 2 (6%)
Not identified 5 (14%)
Medications reported when blood samples collected
Prednisolone (≤10 mg/day) 11 (31%)
Cyclophosphamide 1 (3%)
Nonsteroidal anti-inflammatory drug 5 (14%)
D-Penicillamine 3 (8%)
Oral prostanoid 19 (53%)
Calcium channel blocker 2 (6%)
Statin 6 (17%)
Anti-platelet aggregation 6 (17%)
Antacid 12 (33%)
aThree patients had two systemic sclerosis-related autoantibodies: one patient
with anti-topoisomerase I and anticentromere; one patient with anti-
topoisomerase I and anti-U1 ribonucleoprotein; and one patient with
anticentromere and anti-U1 ribonucleoprotein.
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Cell preparation
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from heparinized venous blood by Lymphoprep™
(Fresenius Kabi Norge, Halden, Norway) density-gradient
centrifugation. CD14+ monocytes were separated from
PBMCs using an anti-CD14 mAb coupled to magnetic
beads (CD14 MicroBeads; Miltenyi Biotech, Bergisch
Gladbach, Germany) followed by magnetic cell sorting col-
umn separation according to the manufacturer’s protocol
[24]. Flow cytometric analysis showed that the sorted frac-
tion consistently contained more than 95% CD14+ cells.
Gene expression profiling
Total RNA was extracted from purified monocytes using
the ArrayGrade™ Total RNA Isolation kit (SABiosciences,
Frederic, MA, USA) according to the manufacturer’s pro-
tocol. Pooled RNA was prepared by mixing equal amounts
of total RNA from five patients with SSc or from five
healthy control subjects. We prepared two different inde-
pendent sets of RNA. The first SSc patient set was com-
posed of RNA from four females and one male with dcSSc
(mean age at examination 40.0 ± 12.3, and mean disease
duration from onset of Raynaud’s phenomenon 9.4 ± 7.1
years). The second set was derived from four females and
one male (four dcSSc and one lcSSc, mean age at exami-
nation 50.4 ± 8.9, and mean disease duration 16.2 ± 10.6
years). We generated biotin-16-uridine-5’-triphosphate-
labeled cRNA probes from pooled total RNA (3 μg) using
reverse transcription and a TrueLabeling-AMP™ 2.0 kit
(SABiosciences). Gene expression was profiled from
pooled total RNA (3 μg) using Oligo GEArray® (SABios-
ciences) according to the manufacturer’s instructions. This
array covers 330 genes encoding ECM and adhesion mole-
cules, chemokines and receptors, and proteins with
endothelial cell functions.
The intensity of individual bands was measured by den-
sitometry with National Institute of Health image software
(Image J; National Institute of Mental Health, Bethesda,
MD, USA). Relative gene expression levels were calculated
as a ratio of the intensity of the target spot to that of glyce-
laldehyde-3-phosphate dehydrogenase. To identify genes
that were upregulated in SSc monocytes, we compared the
expression levels of individual genes in two independent
sets of pooled monocyte RNA obtained from five SSc
patients and from five healthy subjects. We selected candi-
date genes that met both of the following criteria: they
were expressed at higher levels in SSc than in control
monocytes in two independent sets, and they had 1.5-fold
greater expression in SSc than in healthy monocytes in at
least one set [25].
Semiquantitative and quantitative PCR
Total RNA was extracted from monocytes using an
RNeasy® mini kit (Qiagen Inc, Valencia, CA, USA),
first-strand cDNA was reverse-transcribed with an oligo
(dT)12-15 primer (Invitrogen, Carlsbad, CA, USA), and
cDNA equivalent to 2 ng total RNA was used for PCR
analysis. The primer sequences, annealing temperatures,
and cycles used to amplify individual genes are summar-
ized in Table 2. Individual band intensity was quantified by
densitometry. Relative mRNA expression levels were calcu-
lated as a ratio of the band intensity of the target gene to
that of glyceraldehyde-3-phosphate dehydrogenase.
Gene mRNA expression levels were further evaluated
by quantitative PCR using the TaqMan® real-time PCR
system (Applied Biosystems, Foster City, CA, USA)
according to the manufacturer’s protocols. Each gene’s
expression was measured relative to glyceraldehyde-3-
phosphate dehydrogenase. Specific primers and probes
for amplifying genes encoding L-selectin (Hs00174151),
versican (Hs00171642), CCL2 (Hs00234140), CXCL8
(Hs00174103), versican V0 isoform (Hs01007944), and
versican V1 isoform (Hs01007937) were purchased from
Applied Biosystems. In some experiments, high and low
mRNA expression levels were defined according to the
mean plus two standard deviations of the levels in
healthy control samples.
Quantifying proteins in monocyte culture supernatants
Monocytes were plated and cultured in RPMI 1640 con-
taining 10% fetal bovine serum, 50 U/ml penicillin, and
50 μg/ml streptomycin. To measure versican production,
5 × 106 monocytes were cultured in six-well plates with-
out exogenous stimulation. Supernatants were harvested
at 48 hours, concentrated with an Ultra-free MC 30K
filter (Millipore, Billerica, MA, USA), and treated with
chondroitinase ABC (Seikagaku Kogyo, Tokyo, Japan) to
cleave chondroitin sulfate (CS) chains. The samples
were then analyzed by SDS-PAGE, followed by immuno-
blotting with mouse mAb to human versican (clone 2B1;
Seikagaku Kogyo) and horseradish peroxidase-conjugated
goat anti-rabbit secondary antibodies (Thermo Fisher
Scientific, Rockford, IL, USA). Bound antibodies were
detected with a chemiluminescence detection system
(Perkin Elmer Life Sciences, Boston, MA, USA). The sig-
nal intensity of the band corresponding to the molecular
weight of a truncated versican (250 kDa) was quantified
by densitometry. To measure CCL2 production, 105 cells
were cultured in 24-well plates without exogenous stimu-
lation, culture supernatants were harvested at 24 hours,
and CCL2 was measured in culture supernatants using a
Quantikine® ELISA kit (R&D Systems, Abingdon, UK).
Immunocytostaining
The intracellular localization of versican and CCL2 was
determined by immunofluorescence as reported pre-
viously [26]. Briefly, CD14+ monocytes were cultured on
BD BioCoat™ Poly-D-Lysine Cellware (BD Biosciences,
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San Diego, CA, USA) for 2 hours. The cells were fixed
with acetone and incubated with goat anti-human versi-
can polyclonal antibodies (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) in combination with rabbit anti-
human CCL2 polyclonal antibodies (Santa Cruz Biotech-
nology) or a mouse anti-human goldin-97 mAb (clone
CDF4; Invitrogen), followed by incubation with the
appropriate secondary antibodies conjugated to Alexa
Fluor-488 or Alexa Fluor-568 (Invitrogen). For negative
controls, cells were incubated with an isotype-matched
mouse or rat mAb against an irrelevant antigen instead
of the primary antibody. TO-PRO3 (Invitrogen) was
used to counterstain nuclei. Images were taken with a
Fluoview FV1000 confocal laser fluorescence microscope
(Olympus, Tokyo, Japan).
Assessing capacity of CCL2 for binding chondroitin
sulfate
Carbonate buffer (15 mM Na2CO3, 10 mM NaHCO3)
alone or a solution of synthetic CS (Seikagaku Kogyo)
dissolved in carbonate buffer (200 μg/ml) was incubated
in 24-well plastic plates overnight at 4°C. Unbound CS
was removed, and recombinant CCL2 (50 ng/ml; R&D
Systems) was added to the wells and incubated for
2 hours at 37°C. Protein components attached to the
plate were recovered with 2% SDS, applied to immuno-
blots with rabbit anti-CCL2 polyclonal antibody (Abcam,
Cambridge, MA, USA), and visualized with a chemilumi-
nescence detection system.
To assess how binding to CS affected CCL2’s vulner-
ability to protease-mediated degradation, we incubated
recombinant CCL2 in 24-well plastic plates in the pre-
sence or absence of CS at 37°C for 2 hours, and then left
the wells untreated or treated them with elastase (2 mM),
cathepsin G (1 ml; Calbiochem, San Diego, CA, USA), or
trypsin (0.0005%; BD Biosciences) at 37°C for 1 hour.
Protein components were recovered and analyzed by
immunoblots probed with anti-CCL2 polyclonal anti-
body. The signal intensity of the band corresponding to
intact CCL2 (10 kDa) was semi-quantified using densito-
metry. The percentage of intact CCL2 in individual sam-
ples was expressed as a percentage of that found on
pretreated CS-coated wells that did not receive protease
treatment.
Migration assay
Monocyte migration was evaluated as described previously
[27], with some modifications. Briefly, the lower chambers
of 24-well TransWell® plates with 5 μm pore filters (Corn-
ing Incorporated, Corning, NY, USA) were left untreated
(vehicle) or coated with serial concentrations of CS (10,
50, and 250 μg/ml). The wells were incubated with recom-
binant CCL2 (50 ng/ml) for 2 hours at 37°C, after which
monocytes (3 × 105) were placed in the upper chambers
for 2 hours at 37°C with 5% carbon dioxide. Cells in the
lower chambers were counted manually using a hemocyt-
ometer, and migration ratios were calculated as a percen-
tage of the cells induced to migrate by vehicle alone. All
experiments were carried out in duplicate. In some experi-
ments, mouse anti-CCL2 mAb (R&D Systems) or mouse
IgG (3.0 ng/ml; Dako, Glostrup, Demark) was added to
the lower chamber. The relative monocyte migration in
individual experiments was calculated as a percentage of
the migration induced in vehicle-coated wells without
CCL2.
Statistical analysis
All continuous variables were recorded as mean ± stan-
dard deviation, and statistical differences were compared
using a nonparametric Mann-Whitney U test. Categori-
cal variables were compared with Fisher’s exact test or a
chi-square test when appropriate. The correlation
Table 2 Primer sequences, annealing temperatures, and cycles used for semiquantitative PCR
Gene Sense primer (5’ ® 3’) Antisense primer (5’ ® 3’) Annealing temperature (ºC) Cycle
CCL2 agcaagtgtcccaaagaagc gcaatttccccaagtcctg 66 32
Type I collagen a1 cctggatgccatcaaagtct ccttcttgaggttgccagtc 66 33
Versican tcattcaacgtcaccttcca ggtccaaaaatccaaaccaa 66 34
L-selectin tcagctgctctgaaggaaca taaccatgactgccactgga 60 30
CCR1 tcctcacgaaagcctacgaggagagtccaagc ccacggagaggagggagccatttaac 66 30
CXCL8 cagttttgccaaggagtgct attgcatctggcaaccctac 63 27
MMP-2 ccaaggagagctgcaacct ccaaggtccatagctcatcgtc 63 40
CCRL2 ctgggctcatgctggggg tgcagcagtgggtggtgg 60 30
GAPDH tgaacgggaagctcactgg tccaccaccctgttgctgta 60 25
Versican variants
Versican V0 tcaacatctcatgttctccc ttcttcactgtgggtataggtcta 57 34
Versican V1 ggctttgaccagtgcgattac ttcttcactgtgggtataggtcta 57 28
Versican V2 tcaacatctcatgttctccc ccagccatagtcacatgtctc 65 38
Versican V3 ggctttgaccagtgcgattac ccagccatagtcacatgtctc 61 32
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coefficient (r) was determined using a single regression
model.
Results
Identifying genes with altered expression in SSc
monocytes
We used the Oligo GEarray™ system, which can screen
330 genes associated with ECM and adhesion molecules,
chemokines and receptors, and endothelial cell biology,
to compare gene expression profiles in circulating mono-
cytes from SSc patients or healthy controls. We per-
formed two independent analysis sets on mixed total
RNA samples: one set from five SSc patients and the
other from five healthy controls. Based on results of two
independent sets of analysis, we selected collagen type I
a1, versican, L-selectin, matrix metalloproteinase-2,
CCL2, CXCL8, CCR1, and CCRL2 as candidates for
genes preferentially overexpressed in SSc monocytes
(Figure 1). Of these, only versican was confirmed by semi-
quantitative PCR and quantitative TaqMan® real-time
PCR to be significantly upregulated in SSc monocytes.
Figure 2 shows versican mRNA levels, quantified by
TaqMan® real-time PCR, in monocytes from 24 SSc
patients and 13 control subjects (219.9 ± 376.5 vs. 46.2 ±
31.1, P = 0.002). Although CCL2 expression tended to be
higher in SSc patients, the difference was not statistically
significant (P = 0.06). Since CCL2 levels in SSc mono-
cytes varied widely, we increased the number of subjects
sampled (36 patients with SSc, 32 control subjects) and
the difference in CCL2 gene expression between the two
groups reached statistical significance (0.37 ± 0.53 vs.
0.11 ± 0.07, P = 0.04) (Figure 2). The remaining six can-
didate genes were excluded because confirmatory ana-
lyses did not show a statistically significant difference
between their expression levels in SSc and control
monocytes.
Clinical features associated with high versican or CCL2
mRNA expression in monocytes
Versican and CCL2 mRNA levels varied considerably
among SSc monocytes, and high expression levels were
detected in a subgroup of patients. We examined clinical
Figure 1 Gene expression profiles of circulating monocytes from patients with systemic sclerosis and from healthy controls. Two sets
of genes, each set containing RNA from five subjects, were analyzed (RNA pool #1 and #2) with the Oligo GEArray® (SABiosciences, Frederic,
MA, USA). The results for eight candidate genes for genes preferentially overexpressed in systemic sclerosis (SSc) monocytes are shown along
with control (glycelaldehyde-3-phosphate dehydrogenase (GAPDH)).
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Figure 2 Versican and CCL2 mRNA levels in monocytes from patients with systemic sclerosis and healthy controls. Quantitative PCR
analysis. Relative mRNA expression levels were calculated as a ratio of mRNA levels of the genes of interest to those of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). Bars in the graph denote the mean. Differences between the groups were analyzed by Mann-Whitney U
test. SSc, systemic sclerosis.
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features associated with a high level of versican or CCL2
mRNA in circulating monocytes, which were defined
based on above the mean plus two standard deviations
of the levels in healthy control samples. We examined
24 patients with SSc, 11 with high levels and 13 with
low levels of versican expression, and found differences
in the frequencies of dcSSc (82% vs. 25%, P = 0.02),
interstitial lung disease (82% vs. 46%, P = 0.04), positive
anti-topoisomerase I antibody (64% vs. 15%, P = 0.01),
and esophageal involvement (100% vs. 46%, P = 0.006).
In fact, versican levels were significantly higher in
patients with dcSSc than in those with lcSSc (413 ± 531
vs. 100 ± 92, P = 0.03), and in patients with esophageal
involvement than those without (340 ± 459 vs. 54 ± 34,
P = 0.002). In particular, all four patients with an extre-
mely high mRNA expression level of versican (>300)
had dcSSc. We did not find any correlation with clinical
characteristics and the level of CCL2 mRNA expressed
by circulating monocytes in SSc patients.
Upregulated mRNA expression of the versican isoforms
V0 and V1 in SSc monocytes
Versican, or CS proteoglycan 2, is a large extracellular
matrix proteoglycan (>1,000 kDa) that is present in a vari-
ety of human tissues, including skin and blood vessels [28].
Versican consists of an amino-terminal hyaluronan binding
region, a glycosaminoglycan (GAG)-binding domain, and a
C-type lectin-like domain. Numerous CS chains are
attached to a GAG-binding domain (Figure 3A). In addi-
tion to full-length versican (V0), three short isoforms hav-
ing GAG-binding domains of different sizes (V1, V2, and
V3) are generated by alternative splicing (Figure 3B).
We designed PCR primers to detect each of the four
versican isoforms separately, and assessed their mRNA
levels in SSc and control monocytes. Semiquantitative
PCR analysis of monocytes from 30 patients with SSc and
17 healthy controls showed significantly higher mRNA
levels of both V0 and V1 in SSc than in control monocytes
(P = 0.01 for both comparisons), while V2 and V3 levels
were comparable in the two groups (Figure 3C).
TaqMan® real-time PCR confirmed that mRNA
expression of the V0 and V1 isoforms, both of which
have long GAG-binding domains, was upregulated in
SSc patients as compared with healthy control subjects
(Figure 4).
Versican and CCL2 proteins are upregulated in SSc
monocytes
We cultured freshly isolated monocytes without any exo-
genous stimuli, and measured versican and CCL2 pro-
teins spontaneously secreted into the supernatant during
cultures. As shown in Figure 5A, the versican V0 isoform
was concentrated and detected in supernatants by immu-
noblotting. Versican levels were significantly higher in
culture supernatants from SSc monocytes than in those
from healthy control monocytes (P = 0.03) (Figure 5B).
SSc monocytes also produced more CCL2 than did con-
trol monocytes (P = 0.01) (Figure 5C). The mRNA and
protein expression levels in a given patient were corre-
lated with each other for versican (r2 = 0.66, P = 0.003)
and CCL2 (r2 = 0.51, P = 0.004).
Capacity of CCL2 to bind chondroitin sulfate chains
Versican’s negatively charged CS chains can bind to che-
mokines such as CCL2, CCL3, and CCL5 via ionic inter-
actions, and can function as a chemokine reservoir
[28,29]. The versican isoforms V0 and V1, which were
both elevated in SSc monocytes, have numerous CS
chains attached to the GAG-binding domain and thus
have a large capacity for binding chemokines [28]. Both
versican and CCL2 are upregulated in SSc monocytes;
to determine whether these form a complex, we exam-
ined CCL2’s binding capacity using plastic plates coated
with or without synthetic CS (Figure 6A). As expected,
CCL2 was able to bind to the plates only when CS was
present. Immunocytostaining showed the cellular locali-
zation of versican and CCL2 in the Golgi apparatus of
monocytes; the representative images of SSc monocytes
in Figure 6B show versican and CCL2 colocalized in the
Golgi apparatus. Additional experiments using mono-
cytes derived from a patient with SSc and a healthy con-
trol subject produced concordant findings. Since the
Golgi plays an important role in the synthesis of proteo-
glycans [30], these results suggest that versican forms a
complex with CCL2 before secretion by monocytes.
Chondroitin sulfate chains enhance CCL2-mediated
monocyte migration
The chemokine CCL2 induces monocytes, neutrophils,
and lymphocytes to migrate [31]. To examine whether
CCL2’s capacity to induce migration is enhanced by bind-
ing to versican’s CS chains, we performed migration assays
in a TransWell® double-chamber system using CD14+
monocytes derived from healthy controls and SSc patients.
First, monocytes were cultured in the upper chamber, and
the lower chamber was pre-coated with CS or vehicle
alone in the presence or absence of CCL2 (Figure 7A,B).
Monocyte migration was promoted only in the presence
of CS-coated plates treated with CCL2, and the strength
of the effect depended on the CS concentration in the
coating (Figure 7C,D). This enhanced monocyte migration
was completely blocked by adding an anti-CCL2 neutraliz-
ing antibody (Figure 7E,F). Monocytes derived from a
healthy control and an SSc patient showed the similar
behavior. Concordant results were obtained in additional
experiments using monocytes derived from three healthy
controls and three SSc patients. These findings indicate
that CCL2 activity is augmented by binding to CS chains.
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Figure 3 Versican splice variants and mRNA levels in monocytes from systemic sclerosis patients and healthy controls. (A) Molecular
structure of full-length versican (V0), which has numerous chondroitin sulfate (CS) chains attached to its glycosaminoglycan (GAG)-binding
domain. (B) mRNA structures of versican splice variants (V0, V1, V2 and V3). Versican is composed of a hyaluronan binding region (HABR, green),
GAG-binding domains (blue and yellow), and epidermal growth factor-like, lectin-like, and complement-regulatory-like domains (EELC, red).
Individual mRNA components are shown in the same color as their corresponding protein structures. Arrows denote primers used to amplify
each splice variant. (C) Levels of versican V0, V1, V2, and V3 mRNA in systemic sclerosis (SSc) and control monocytes, analyzed using
semi-quantitative PCR. Relative mRNA levels were calculated as a ratio of the expression level of the gene of interest to that of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). Each bar in the graph denotes the mean. Differences between the two groups were analyzed by
Mann-Whitney U test. NS, not significant.
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Figure 4 Versican V0 and V1 mRNA levels in systemic sclerosis and control monocytes. Quantitative PCR analysis. Relative mRNA levels
were calculated as a ratio of the level of the gene of interest to that of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Each bar in the
graph denotes the mean. Differences between the groups were analyzed by Mann-Whitney U test. SSc, systemic sclerosis.
Figure 5 Versican V0 and CCL2 protein levels in monocyte culture supernatants. Versican V0 and CCL2 protein levels in monocyte culture
supernatants derived from systemic sclerosis (SSc) patients and healthy controls. (A) Representative immunoblot evaluating versican V0 protein
expression. Monocyte culture supernatants were concentrated, truncated, and applied to immunoblots. (B) Versican V0 protein levels in
monocytes from 14 patients with SSc and 11 healthy controls, semiquantitatively measured by densitometry. (C) CCL2 protein levels in
monocytes from 16 patients with SSc and 13 healthy controls. CCL concentration in culture supernatants was measured by an ELISA. Each bar in
the graph denotes the mean. Results from the two groups were compared by Mann-Whitney U test.
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Enhanced CCL2-mediated monocyte migration was prob-
ably due to the efficient formation of a chemotactic gradi-
ent, but it was also possible that CCL2 was protected from
degradation when bound to a CS chain. To test this hypoth-
esis, CCL2 was incubated with plates treated with CS or
vehicle, and exposed to a variety of proteases that included
elastase, cathepsin G, and trypsin. As shown in Figure 8A,
CCL2 was degraded in the presence of proteases, but was
protected from protease-mediated degradation when bound
to the CS-coated plates. Concordant findings were obtained
from three healthy controls (Figure 8B).
Discussion
This study has demonstrated that versican and CCL2
are upregulated in circulating CD14+ monocytes in a
subset of SSc patients. High versican levels in circulating
monocytes were associated with fibrotic characteristics
of SSc, such as diffuse cutaneous involvement. Interest-
ingly, versican forms a reservoir for various CC chemo-
kines that induce the migration of circulating
monocytes, which produce additional versican after
arriving at the versican-rich site. CCL2’s ability to
induce monocytes to migrate is enhanced by its binding
to versican, due to the efficient formation of chemokine
gradients and protection from proteolytic degradation.
This positive feedback loop, consisting of versican,
CCL2, and the influx of monocytes, may be enhanced at
the affected sites of a subset of SSc patients with pheno-
typically altered circulating monocytes.
Versican is involved in many physiologic and patholo-
gic processes, including neuronal development [32],
atherosclerosis [33], and the invasive and metastatic
Figure 6 Formation of CCL2 and versican complex in circulating monocytes. (A) CCL2 was incubated with plastic plates coated with
chondroitin sulfate (CS) or vehicle. Bound CCL2 was recovered and subjected to immunoblots (lanes 2 and 3, respectively). Lane 1, untreated
CCL2 as a positive control. A representative result from three experiments is shown. (B) Versican and CCL2 cellular localization in monocytes
from an systemic sclerosis (SSc) patient, assessed by multi-color immunocytostaining: upper panel, CCL2 (green), versican (red), and their merged
image; lower panel, goldin-97 (green), versican (red), and their merged image. Nuclei were counterstained with TO-PRO3 (blue). A representative
result from three independent experiments is shown. Original magnification, ×600.
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signatures of many cancers [34]. As with other ECM
components, versican is enriched in the skin of patients
with SSc [35], although little is known about versican’s
role in SSc pathogenesis. Versican is able to bind type I
collagen and hyaluronic acid to maintain the integrity of
the ECM [28], which may be important in forming the
stiff fibrotic tissue seen with SSc. Versican also functions
as a unique reservoir for a variety of growth factors,
chemokines, and cytokines, which it gathers via numer-
ous CS chains attached to its GAG-binding domain
[28]. Chemokines known to bind versican include CCL2,
CCL3, CCL5, CCL21, CXCL10, and CXCL12. It is
Figure 7 CCL2 chemoattractant activity promoting monocyte migration, with or without chondroitin sulfate binding. Circulating
monocytes derived from healthy controls (A, C, E) and systemic sclerosis (SSc) patients (B, D, F). (A, B) CCL2-induced monocyte migration in the
presence or absence of chondroitin sulfate (CS) coating. Lower chambers of a TransWell® double-chamber system (Corning Incorporated,
Corning, NY, USA) were coated with CS or vehicle, and CD14+ monocytes were applied to the upper chambers. (C, D) CCL2-induced monocyte
migration on plastic plates precoated with serial concentrations of CS. (E, F) CCL2-induced monocyte migration on CS-coated plastic plates in
the presence of anti-CCL2 mAb or control IgG. Relative monocyte migration was calculated as a percentage of migration in a control
experiment using vehicle-coated wells without CCL2. All experiments were carried out in duplicate; the mean and standard deviation of three
measurements is shown. Results from the two groups were compared using a Mann-Whitney U test. A representative result from four
independent experiments is shown.
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particularly noteworthy that versican generates a chemo-
tactic gradient of CC chemokines that attracts circulat-
ing monocytes and T cells to versican-rich sites [36].
Versican subsequently promotes the adhesion and activa-
tion of recruited monocytes through binding to adhesion
receptors such as integrins and CD44 on cell surfaces
[37]. Through these processes, versican generates a com-
plex set of environmental cues for infiltrating mononuc-
lear cells and resident cells [28].
Interestingly, monocytes and monocyte-derived cells
are not only recruited by versican, but are also major pro-
ducers of versican [38,39]. Therefore, after migrating to
versican-rich sites, these monocytes amplify the tissue
response by producing more versican, which in turn pro-
motes the influx of more monocytes [40]. In this regard,
recent studies indicate that the positive feedback loop
formed by versican and monocyte-lineage cells is critical
for inducing certain pathologic conditions, such as tumor
invasion and metastasis [41] and the formation of athero-
sclerotic plaques [38]. In patients with SSc, this versican-
mediated positive feedback loop probably contributes to
the fibrotic process by recruiting certain subsets of
monocytes that acquire profibrotic properties [6,15]. The
mechanisms that initially stimulate the release of versican
in the early stages of SSc remain elusive, but once this
positive feedback loop is established the profibrotic
response would, theoretically, be amplified endlessly.
CCL2, a chemokine known to be involved in patho-
genic process of SSc [42], is also elevated in circulating
monocytes from SSc patients. Levels of circulating CCL2
were elevated in SSc patients, especially in those with
early dcSSc [43,44] or interstitial lung disease [43,45,46].
A recent longitudinal analysis in patients with dcSSc
found that circulating CCL2 decreases year after year,
along with improvements in skin sclerosis [47], suggest-
ing CCL2 as an indicator of profibrotic activity in
patients with SSc. Several animal models of tissue fibrosis
have demonstrated CCL2’s crucial role in the fibrotic
process, in which attenuating CCL2 activity prevents tis-
sue fibrosis. Mice lacking CCL2 are protected from bleo-
mycin-induced dermal fibrosis [48], while mice lacking
the CCL2 receptor CCR2 are protected from bleomycin-
induced lung fibrosis [49,50]. In these models, monocyte
infiltration and collagen deposition were remarkably
lower than in wild-type mice. The present study raises
the question of which cell type producing CCL2 is more
likely to be important for SSc pathogenesis. In this
regard, abundant expression of CCL2 was observed in
fibroblasts and mononuclear cells in the skin of SSc
patients [45,51,52]. CCL2 has also been reported to be
expressed mainly by infiltrating monocytes early in the
disease, whereas fibroblasts become the major source for
CCL2 in the skin later in the disease [42]. Unfortunately,
our ex vivo analysis failed to demonstrate which cell type
is the primary source of CCL2 involved in the pathogenic
process of SSc.
Despite this definitive role of CCL2 in the develop-
ment of excessive fibrosis in vivo, the details of the pro-
fibrotic mechanisms remain unclear. Yamamoto and
colleagues reported that CCL2 significantly increased
the levels of collagen mRNA expressed in cultured
dermal fibroblasts [53], but another study failed to
Figure 8 Binding to chondroitin sulfate chains protects CCL2 from protease-mediated degradation. (A) CCL2 was pre-incubated with
chondroitin sulfate (CS) or vehicle, and treated with a series of proteases including elastase, cathepsin G, and trypsin. A representative
immunoblot from three different experiments shows a band corresponding to intact CCL2 (10 kDa). (B) Amount of intact CCL2 in individual
wells precoated with CS or vehicle, and subsequently treated with a series of proteases. Mean and standard deviation of three independent
measurements is shown. The quantity of intact CCL2 in individual samples was expressed as a percentage of the quantity of CCL2 on wells
precoated with CS and not treated with protease.
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reproduce this finding [54]. While CCR2 is generally not
expressed by fibroblasts, Carulli and colleagues found
that CCR2 is expressed by a small population of fibro-
blasts derived from patients with early dcSSc [55].
CCL2’s profibrotic effects may thus require interaction
with other cell types that express CCR2, such as mono-
cytes and T cells. In this regard, it has been shown in
SSc patients that CCL2 induces infiltrating CD4+ T cells
to differentiate into T-helper 2 cells, which release
higher amounts of IL-4 and stimulate fibroblasts to pro-
duce excess ECM [54]. In this scenario, versican func-
tions as a local reservoir for CCL2 and, whether bound
to or released from versican, CCL2 is capable of effi-
ciently stimulating T cells. In addition to its role in this
T-cell-mediated mechanism, CCL2 also contributes to
fibrotic response by promoting the migration and accu-
mulation of profibrotic monocytes at affected sites in
SSc patients. All together, the upregulation of versican
and CCL2 in circulating monocytes accelerates CCL2-
mediated profibrotic responses in SSc patients.
What mechanisms assist in shaping circulating mono-
cytes to the profibrotic phenotype seen in patients with
SSc? One of histopathological hallmarks of SSc is the
perivascular infiltration of monocytes early in the dis-
ease [4]. It is possible that intrinsically altered mono-
cytes migrate into target organs and trigger a profibrotic
response by stimulating resident fibroblasts. Alterna-
tively, monocyte phenotypes may be altered in SSc
patients by the strong profibrotic environment. Versican
production is highly regulated by soluble factors and
certain stimuli, and several studies have reported that
profibrotic growth factors such as transforming growth
factor beta, platelet-derived growth factor, and basic
fibroblast growth factor upregulate versican synthesis
[56-58]. These factors are also known to upregulate
CCL2 expression [59,60]. In contrast, IFNg and IL-1b
reduce versican expression [61,62]. Hypoxia dramatically
upregulates versican in macrophages via hypoxia-induci-
ble factor signaling [38]. The profibrotic and hypoxic
environment associated with SSc may modulate gene
expression profiles of circulating monocytes.
Genes selected by initial screening via gene expression
array but excluded by confirmatory analyses may be of
some interest, because some of them have been reported
as molecules associated with SSc pathogenesis. For
example, circulating levels of soluble L-selectin and
CXCL8 were increased in SSc patients versus healthy
controls [63,64]. In addition, gene expression of CCR1
was shown to be upregulated in PBMCs derived from
patients with lcSSc and pulmonary arterial hypertension
[65].
There are several limitations to this study. First, we
used total CD14+ monocytes enriched form PBMCs,
which contained CD14+ fibrocyte precursors [9]. Since
fibrocyte precursors are reported to be a rare cell popu-
lation, comprising approximately 0.5% of circulating
monocytes [66], contamination of them into CD14+
cells should have minimal impact on gene and protein
expression data. Second, prominent upregulation of ver-
sican and CCL2 in circulating monocytes was observed
in a minority of SSc patients, raising a possibility that
the monocytic versican-mediated pathogenic process is
only one of the roles of circulating monocytes in the
pathogenesis of SSc. Since all patients with an extremely
high mRNA expression level of versican had dcSSc, this
type of monocyte phenotypic change might be unique
to patients with a prominent fibrotic phenotype. Finally,
this study represented only an in vitro functional inter-
action between versican and CCL2, which may not
reflect in vivo activity. In addition, overexpression of
versican in circulating monocytes of SSc patients might
be a bystander of other more important pathogenic pro-
cess of SSc. Further investigations involving genetically
manipulated animals- for example, mice lacking func-
tional versican expression specifically in monocytes - is
necessary to confirm a critical role of versican upregu-
lated by circulating monocytes in SSc pathogenesis.
Conclusion
The cellular and molecular mechanisms underlying the
SSc fibrotic process primarily involve the interaction of
cells such as fibroblasts, endothelial cells, and circulating
immune cells, orchestrated by profibrotic soluble media-
tors and ECM components. This concept is supported
by our observation that circulating monocytes in SSc
patients are phenotypically altered and amplify a positive
feedback loop, mediated by versican and CCL2, between
monocytes and fibroblasts. Further studies evaluating
the roles of circulating monocytes in the pathogenic
process of SSc should help to elucidate the complex
pathophysiology of SSc and assist us to develop novel
therapeutic strategies in this multisystem fibrotic
disease.
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